5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Acinetobacter Infections, drug therapy, microbiology, Acinetobacter baumannii, drug effects, Aged, Anti-Bacterial Agents, therapeutic use, Colistin, Drug Resistance, Multiple, Bacterial, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, Pneumonia, Bacterial, Pseudomonas Infections, Pseudomonas aeruginosa, Retrospective Studies

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.

          Related collections

          Author and article information

          Comments

          Comment on this article